Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Pharmacoepidemiol Drug Saf. 2024 Oct;33(10):e70023. doi: 10.1002/pds.70023.
We aimed to investigate the awareness of oral retinoid teratogenicity and the adherence to the pregnancy prevention program (PPP) related to oral retinoid use by physicians, pharmacists, and patients in Denmark.
As part of the multi-country survey, web-based questionnaires were distributed among Danish dermatologists, general practitioners, community pharmacists, and women of childbearing age, who were using or had used oral retinoids within the past 5 years.
A total of 62 physicians, 96 pharmacists, and 50 oral retinoid using women responded; 95%, 100%, and 98%, respectively, were aware of the teratogenic risks of oral retinoids. For physicians, the most applied PPP measures were the usage of the patient (44%) and the healthcare professional (19%) guides, while the least applied measure was signing medication risk awareness form (3%). Among the pharmacists, the warning sign on the outer medication package was the most used measure (45%). Among the women, a majority (90%) had read the patient information leaflet included in the medication package and 72% discussed the use of contraception with their healthcare provider, while risk awareness forms and patient cards were seen by only few.
In Denmark, physicians, pharmacists, and medicine users were aware about the teratogenic effects of oral retinoids. Adherence to pregnancy prevention measures varied, suggesting unwillingness to use the measures that require patients' signatures among physicians and a lack of awareness of pharmacy targeting measures. Accessibility of the latter measures need to be optimized to improve the safety of oral retinoid use.
我们旨在调查丹麦的医生、药剂师和患者对口服类维 A 酸致畸性的认识，以及对与口服类维 A 酸使用相关的妊娠预防计划（PPP）的依从性。
作为多国家调查的一部分，我们向丹麦皮肤科医生、全科医生、社区药剂师和在过去 5 年内使用或曾使用过口服类维 A 酸的育龄妇女发放了基于网络的调查问卷。
共有 62 名医生、96 名药剂师和 50 名正在使用或曾使用过口服类维 A 酸的女性做出了回应；分别有 95%、100%和 98%的人知晓口服类维 A 酸的致畸风险。对于医生而言，最常应用的 PPP 措施是使用患者（44%）和医疗保健专业人员（19%）指南，而最不常应用的措施是签署药物风险意识表（3%）。在药剂师中，药物外包装上的警告标志是最常使用的措施（45%）。在女性中，大多数（90%）人阅读了药物包装内的患者信息传单，且 72%的人曾与医疗保健提供者讨论过避孕问题，而仅有少数人见过风险意识表和患者卡片。
在丹麦，医生、药剂师和药物使用者都知晓口服类维 A 酸的致畸作用。对妊娠预防措施的依从性各不相同，这表明医生不愿意使用需要患者签名的措施，且药剂师缺乏对药物靶向措施的认知。需要优化后者的可及性，以提高口服类维 A 酸使用的安全性。
